After one to four years of tamoxifen, switching to anastrozole improves disease-free survival by about 31 percent, but patients pay a price in quality of life measures. The difference in quality of life is significant enough that scientists say it should be considered, and may even be the deciding factor, when making a clinical decision about therapeutic strategy.